SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: GlobeNewswire
NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) (NASDAQ: AVIR). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Atea and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On October 19, 2021, Atea issued a press release “report[ing] that the global Phase 2 MOONSONG trial evaluating AT-527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms.” Accordingly, Atea stated that it was “assessing potential modification
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsGlobeNewswire
- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
AVIR
Earnings
- 2/28/24 - Miss
AVIR
Sec Filings
- 2/28/24 - Form 10-K
- 2/28/24 - Form 8-K
- 2/15/24 - Form SC
- AVIR's page on the SEC website